Cerus (NASDAQ:CERS) COO Sells 42,359 Shares of Stock

by · The Cerbat Gem

Cerus Corporation (NASDAQ:CERS – Get Free Report) COO Vivek Jayaraman sold 42,359 shares of the business’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $2.94, for a total value of $124,535.46. Following the sale, the chief operating officer owned 1,694,348 shares of the company’s stock, valued at approximately $4,981,383.12. The trade was a 2.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Cerus Trading Up 5.3%

Shares of NASDAQ:CERS traded up $0.16 during trading on Thursday, hitting $3.16. 3,286,738 shares of the company’s stock were exchanged, compared to its average volume of 2,750,392. Cerus Corporation has a 1-year low of $1.15 and a 1-year high of $3.21. The firm has a 50-day moving average price of $2.59 and a two-hundred day moving average price of $2.29. The company has a current ratio of 1.63, a quick ratio of 1.06 and a debt-to-equity ratio of 0.47. The firm has a market cap of $633.17 million, a P/E ratio of -63.20 and a beta of 1.77.

Cerus (NASDAQ:CERS – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. The business had revenue of $59.89 million during the quarter, compared to the consensus estimate of $55.68 million. Cerus had a negative return on equity of 15.18% and a negative net margin of 4.41%. Equities analysts predict that Cerus Corporation will post -0.02 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on CERS. BTIG Research raised shares of Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price objective on the stock in a research report on Friday, May 1st. Zacks Research upgraded Cerus from a “strong sell” rating to a “hold” rating in a report on Thursday, April 30th. Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cerus in a research note on Thursday, June 18th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $4.00.

Check Out Our Latest Report on Cerus

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CERS. Cibc World Markets Corp bought a new stake in Cerus in the fourth quarter valued at approximately $25,000. CIBC Bancorp USA Inc. acquired a new stake in Cerus during the 3rd quarter worth about $31,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Cerus in the 1st quarter valued at about $32,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Cerus during the 1st quarter worth approximately $35,000. Finally, Aquatic Capital Management LLC bought a new position in Cerus in the third quarter worth approximately $35,000. 78.37% of the stock is owned by institutional investors and hedge funds.

About Cerus

(Get Free Report)

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.

Read More